Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study

Passoni, Niccolò; Shariat, Shahrokh F.; Bagrodia, Aditya; Francis, Franto; Rachakonda, Varun; Xylinas, Évanguelos; Kapur, Payal; Sagalowsky, Arthur I.; Lotan, Yair

doi:10.3233/blc-150036

Cited by 9 publications

(5 citation statements)

References 30 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…found a high concordance rate (between 77.5% and 92.2%) for the expression of p53, p21, p27, Ki67 and cyclin E1 between TURBT and matched radical cystectomy specimens. P53 and p21 showed the lowest concordance rate, while cyclin E1 showed the highest, suggesting that this correlation could help in risk stratification of patients ( 25 ).…”

Section: Prognostic Biomarkers In Nmibcmentioning

confidence: 90%

Non-muscle invasive bladder cancer biomarkers beyond morphology

et al. 2022

View full text Add to dashboard Cite

Non-muscle invasive bladder cancer (NMIBC) still represents a challenge in decision-making and clinical management since prognostic and predictive biomarkers of response to treatment are still under investigation. In addition to the risk factors defined by EORTC guidelines, histological features have also been considered key variables able to impact on recurrence and progression in bladder cancer. Conversely, the role of genomic rearrangements or expression of specific proteins at tissue level need further assessment in NMIBC. As with muscle-invasive cancer, NMIBC is a heterogeneous disease, characterized by genomic instability, varying rates of mutation and a wide range of protein tissue expression. In this Review, we summarized the recent evidence on prognostic and predictive tissue biomarkers in NMIBC, beyond morphological parameters, outlining how they could affect tumor biology and consequently its behavior during clinical care. Our aim was to facilitate clinical evaluation of promising biomarkers that may be employed to better stratify patients. We described the most common molecular events and immunohistochemical protein expressions linked to recurrence and progression. Moreover, we discussed the link between available treatments and molecular drivers that could be predictive of clinical response. In conclusion, we foster further investigations with particular focus on immunohistochemical evaluation of tissue biomarkers, a promising and cost-effective tool for daily practice.

show abstract

Section: Prognostic Biomarkers In Nmibcmentioning

confidence: 90%

Non-muscle invasive bladder cancer biomarkers beyond morphology

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Overall, pretreatment molecular characterization of TURBT samples holds the promise to help select the UCB patient who is most likely to benefit from NAST [55]. However, due to the lack of prospective, well designed, large-scale data, no molecular biomarkers can be currently recommended for routine use.…”

Section: Tissue-based Biomarkersmentioning

confidence: 99%

Molecular biomarkers to help select neoadjuvant systemic therapy for urothelial carcinoma of the bladder

Laukhtina

Pradère

Lemberger

et al. 2022

Current Opinion in Urology

Self Cite

View full text Add to dashboard Cite

Purpose of reviewIn this review, we aimed to summarize the available evidence on pretreatment molecular biomarkers that may help to predict oncologic and pathologic outcomes in patients treated with neoadjuvant systemic therapy (NAST) for urothelial carcinoma of the bladder (UCB).Recent findingsSeveral readily available and easily measurable blood-based biomarkers (e.g., neutrophil to lymphocyte or platelet–lymphocyte ratios) seems to help improve the selection of UCB patients who are most likely to benefit from NAST. Recent evidence suggests liquid biopsy including circulating tumor DNA (ctDNA) to be a promising tool to guide the administration of NAST in UCB patients. Pretreatment molecular and genetic characterization of transurethral resection of the bladder tumor samples may also help understand the tumor biology as luminal and basal tumor subtypes seems to be more responsive to NAST, while claudin-low and luminal-infiltrated tumor subtypes are less. In the context of neoadjuvant immunotherapy, programmed death-ligand 1 (PD-L1) status and ctDNA remain the only biomarker with possible value as the clinical utility of tumor mutational burden remains controversial/poor.SummaryBiomarker approach is a necessary step to usher the age of precision/personalized medicine for muscle-invasive UCB with the overarching good to prevent both over- and under-therapy. The present review may offer a robust framework to compare and assess current and future molecular biomarkers for the selection of NAST in muscle-invasive UCB.

show abstract

“…In light of the limitations of standard clinicopathologic features as prognostic variables for patients with T1 disease, it is clear that a need exists for more refined risk stratification. In this regard, there has been a growing effort to develop a molecular classification of bladder cancer [34,35].…”

Section: Summary and Final Treatment Recommendationmentioning

confidence: 99%

How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder?

Shariat

Catto

2021

European Urology Oncology

View full text Add to dashboard Cite

This case presents a 64-yr-old, healthy man who noted microscopic haematuria and immediately sought an appointment with the physician. He was a long-term heavy smoker, which alerts the physician to bladder cancer. The standard practice in Austria includes an ultrasound scan, which revealed a small lesion in the bladder of this patient. Cytology is suspicious for high-grade cancer, and transurethral resection of the bladder (TURB) reveals a single primary unifocal 2.0-cm tumour on the left side. During TURB with blue light using hexaminolevulinate (Hexvix), there were two foci of concomitant carcinoma in situ (CIS). The pathology revealed PT1 high grade without lymphovascular invasion or variant histology, with two foci of CIS, that is, a pure urothelial T1 2.0-cm unifocal nonmuscle-invasive bladder cancer (NMIBC) lesion. At this point, the physician opted for a repeat TURB (re-TURB). This revealed no residual tumour, and the computed tomography (CT) urogram was normal as well. The question is: What is the best treatment for this patient? 2. Option A: the case for conservative therapy Why should we choose conservative intravesical treatment in this patient-a healthy 64-yr-old man with T1 grade 3

show abstract

Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study

Cited by 9 publications

References 30 publications

Non-muscle invasive bladder cancer biomarkers beyond morphology

Non-muscle invasive bladder cancer biomarkers beyond morphology

Molecular biomarkers to help select neoadjuvant systemic therapy for urothelial carcinoma of the bladder

How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder?

Contact Info

Product

Resources

About